Financhill
Sell
33

APYX Quote, Financials, Valuation and Earnings

Last price:
$1.58
Seasonality move :
5.24%
Day range:
$1.54 - $1.61
52-week range:
$0.97 - $2.80
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.12x
P/B ratio:
5.35x
Volume:
88.6K
Avg. volume:
78.2K
1-year change:
-37.2%
Market cap:
$59.1M
Revenue:
$52.3M
EPS (TTM):
-$0.83

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
APYX
Apyx Medical
$11.4M -$0.19 -11.23% -41.96% --
CATX
Perspective Therapeutics
$237.9K -$0.20 -- -70.12% --
INFU
InfuSystems Holdings
$34.5M $0.05 9.85% 1713.24% --
RVP
Retractable Technologies
-- -- -- -- --
VTAK
Catheter Precision
$290K -$2.60 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$29.3M -$0.02 11.16% -33.33% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
APYX
Apyx Medical
$1.57 -- $59.1M -- $0.00 0% 1.12x
CATX
Perspective Therapeutics
$2.85 -- $192.6M -- $0.00 0% 15.39x
INFU
InfuSystems Holdings
$8.31 -- $176.7M 131.26x $0.00 0% 1.35x
RVP
Retractable Technologies
$0.64 -- $19.2M -- $0.00 0% 0.50x
VTAK
Catheter Precision
$0.33 -- $2.6M 0.38x $0.00 0% 0.88x
XTNT
Xtant Medical Holdings
$0.36 -- $50M -- $0.00 0% 0.42x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
APYX
Apyx Medical
75.41% 1.369 78.52% 4.30x
CATX
Perspective Therapeutics
-- -5.312 -- --
INFU
InfuSystems Holdings
33.51% 2.847 19.66% 1.37x
RVP
Retractable Technologies
1.55% 0.611 11.72% 5.80x
VTAK
Catheter Precision
12% -11.532 128.21% 0.53x
XTNT
Xtant Medical Holdings
43.2% 1.226 37.09% 0.81x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
APYX
Apyx Medical
$7M -$3.6M -56.85% -132.8% -28.15% -$4.6M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
INFU
InfuSystems Holdings
$19M $3.3M 1.77% 2.8% 9.23% $6.4M
RVP
Retractable Technologies
-$14.8K -$5.1M -16.57% -16.83% -18.58% -$6.5M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
XTNT
Xtant Medical Holdings
$16.3M -$3.8M -22.96% -35.98% -13.47% -$3.8M

Apyx Medical vs. Competitors

  • Which has Higher Returns APYX or CATX?

    Perspective Therapeutics has a net margin of -40.94% compared to Apyx Medical's net margin of --. Apyx Medical's return on equity of -132.8% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    APYX
    Apyx Medical
    60.54% -$0.14 $45.1M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About APYX or CATX?

    Apyx Medical has a consensus price target of --, signalling upside risk potential of 80.47%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that Perspective Therapeutics has higher upside potential than Apyx Medical, analysts believe Perspective Therapeutics is more attractive than Apyx Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    APYX
    Apyx Medical
    0 0 0
    CATX
    Perspective Therapeutics
    0 0 0
  • Is APYX or CATX More Risky?

    Apyx Medical has a beta of 1.273, which suggesting that the stock is 27.326% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

  • Which is a Better Dividend Stock APYX or CATX?

    Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APYX or CATX?

    Apyx Medical quarterly revenues are $11.5M, which are larger than Perspective Therapeutics quarterly revenues of --. Apyx Medical's net income of -$4.7M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, Apyx Medical's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 1.12x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APYX
    Apyx Medical
    1.12x -- $11.5M -$4.7M
    CATX
    Perspective Therapeutics
    15.39x -- -- -$15.1M
  • Which has Higher Returns APYX or INFU?

    InfuSystems Holdings has a net margin of -40.94% compared to Apyx Medical's net margin of 5.12%. Apyx Medical's return on equity of -132.8% beat InfuSystems Holdings's return on equity of 2.8%.

    Company Gross Margin Earnings Per Share Invested Capital
    APYX
    Apyx Medical
    60.54% -$0.14 $45.1M
    INFU
    InfuSystems Holdings
    53.92% $0.08 $83.5M
  • What do Analysts Say About APYX or INFU?

    Apyx Medical has a consensus price target of --, signalling upside risk potential of 80.47%. On the other hand InfuSystems Holdings has an analysts' consensus of -- which suggests that it could grow by 69.98%. Given that Apyx Medical has higher upside potential than InfuSystems Holdings, analysts believe Apyx Medical is more attractive than InfuSystems Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    APYX
    Apyx Medical
    0 0 0
    INFU
    InfuSystems Holdings
    0 0 0
  • Is APYX or INFU More Risky?

    Apyx Medical has a beta of 1.273, which suggesting that the stock is 27.326% more volatile than S&P 500. In comparison InfuSystems Holdings has a beta of 1.528, suggesting its more volatile than the S&P 500 by 52.819%.

  • Which is a Better Dividend Stock APYX or INFU?

    Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. InfuSystems Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical pays -- of its earnings as a dividend. InfuSystems Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APYX or INFU?

    Apyx Medical quarterly revenues are $11.5M, which are smaller than InfuSystems Holdings quarterly revenues of $35.3M. Apyx Medical's net income of -$4.7M is lower than InfuSystems Holdings's net income of $1.8M. Notably, Apyx Medical's price-to-earnings ratio is -- while InfuSystems Holdings's PE ratio is 131.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 1.12x versus 1.35x for InfuSystems Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APYX
    Apyx Medical
    1.12x -- $11.5M -$4.7M
    INFU
    InfuSystems Holdings
    1.35x 131.26x $35.3M $1.8M
  • Which has Higher Returns APYX or RVP?

    Retractable Technologies has a net margin of -40.94% compared to Apyx Medical's net margin of -18.58%. Apyx Medical's return on equity of -132.8% beat Retractable Technologies's return on equity of -16.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    APYX
    Apyx Medical
    60.54% -$0.14 $45.1M
    RVP
    Retractable Technologies
    -0.14% -$0.07 $84.8M
  • What do Analysts Say About APYX or RVP?

    Apyx Medical has a consensus price target of --, signalling upside risk potential of 80.47%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that Apyx Medical has higher upside potential than Retractable Technologies, analysts believe Apyx Medical is more attractive than Retractable Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    APYX
    Apyx Medical
    0 0 0
    RVP
    Retractable Technologies
    0 0 0
  • Is APYX or RVP More Risky?

    Apyx Medical has a beta of 1.273, which suggesting that the stock is 27.326% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

  • Which is a Better Dividend Stock APYX or RVP?

    Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

  • Which has Better Financial Ratios APYX or RVP?

    Apyx Medical quarterly revenues are $11.5M, which are larger than Retractable Technologies quarterly revenues of $10.3M. Apyx Medical's net income of -$4.7M is lower than Retractable Technologies's net income of -$1.9M. Notably, Apyx Medical's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 1.12x versus 0.50x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APYX
    Apyx Medical
    1.12x -- $11.5M -$4.7M
    RVP
    Retractable Technologies
    0.50x -- $10.3M -$1.9M
  • Which has Higher Returns APYX or VTAK?

    Catheter Precision has a net margin of -40.94% compared to Apyx Medical's net margin of -4291.67%. Apyx Medical's return on equity of -132.8% beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    APYX
    Apyx Medical
    60.54% -$0.14 $45.1M
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About APYX or VTAK?

    Apyx Medical has a consensus price target of --, signalling upside risk potential of 80.47%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 506.06%. Given that Catheter Precision has higher upside potential than Apyx Medical, analysts believe Catheter Precision is more attractive than Apyx Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    APYX
    Apyx Medical
    0 0 0
    VTAK
    Catheter Precision
    0 0 0
  • Is APYX or VTAK More Risky?

    Apyx Medical has a beta of 1.273, which suggesting that the stock is 27.326% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

  • Which is a Better Dividend Stock APYX or VTAK?

    Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APYX or VTAK?

    Apyx Medical quarterly revenues are $11.5M, which are larger than Catheter Precision quarterly revenues of $96K. Apyx Medical's net income of -$4.7M is lower than Catheter Precision's net income of -$4.1M. Notably, Apyx Medical's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 1.12x versus 0.88x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APYX
    Apyx Medical
    1.12x -- $11.5M -$4.7M
    VTAK
    Catheter Precision
    0.88x 0.38x $96K -$4.1M
  • Which has Higher Returns APYX or XTNT?

    Xtant Medical Holdings has a net margin of -40.94% compared to Apyx Medical's net margin of -17.98%. Apyx Medical's return on equity of -132.8% beat Xtant Medical Holdings's return on equity of -35.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    APYX
    Apyx Medical
    60.54% -$0.14 $45.1M
    XTNT
    Xtant Medical Holdings
    58.37% -$0.04 $80.5M
  • What do Analysts Say About APYX or XTNT?

    Apyx Medical has a consensus price target of --, signalling upside risk potential of 80.47%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 525%. Given that Xtant Medical Holdings has higher upside potential than Apyx Medical, analysts believe Xtant Medical Holdings is more attractive than Apyx Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    APYX
    Apyx Medical
    0 0 0
    XTNT
    Xtant Medical Holdings
    0 0 0
  • Is APYX or XTNT More Risky?

    Apyx Medical has a beta of 1.273, which suggesting that the stock is 27.326% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

  • Which is a Better Dividend Stock APYX or XTNT?

    Apyx Medical has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Apyx Medical pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios APYX or XTNT?

    Apyx Medical quarterly revenues are $11.5M, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. Apyx Medical's net income of -$4.7M is higher than Xtant Medical Holdings's net income of -$5M. Notably, Apyx Medical's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Apyx Medical is 1.12x versus 0.42x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    APYX
    Apyx Medical
    1.12x -- $11.5M -$4.7M
    XTNT
    Xtant Medical Holdings
    0.42x -- $27.9M -$5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 21

Quantum [QMCO] is up 26.28% over the past day.

Sell
46
NUKK alert for Dec 21

Nukkleus [NUKK] is down 22.94% over the past day.

Sell
1
IIPR alert for Dec 21

Innovative Industrial Properties [IIPR] is down 22.7% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock